AstraZeneca
factor inhibitor complement mediated disease | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2024
Slide
150 of 157
Similar slides by AstraZeneca
See diffirences between slides (animation)
Results
November 2024
factor inhibitor ophthalmology | AstraZeneca
Results
November 2024
targeting complement nephrology | AstraZeneca
Results
November 2024
kidney targeted factor fusion protein nephrology | AstraZeneca
Results
November 2024
next generation bone metabolism | AstraZeneca
Related slides by other companies
Immix Biopharma
Investor Presentation
August 2023
direct path to line therapy in clinical trial plan cold | Immix Biopharma
Immix Biopharma
Investor Presentation
November 2023
direct path to line therapy in clinical trial plan cold | Immix Biopharma
Alkermes
Investor Day
March 2021
agents that induce immunogenic cell death may offer synergistic advantages in combination with combination with radiation chemotherapy or radiation immune inhibitors anti ongoing clinical trials anti growth factor pathway inhibitors tyrosine kinase inhibitors anti antibodies cytotoxic chemotherapies radiation activated cancer fighting cells pharmacotherapy alkermes | Alkermes
Immix Biopharma
Investor Presentation
December 2023
direct path to line therapy in clinical trial plan cold | Immix Biopharma
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights